PMID: 58988Jun 1, 1976

Immunopharmacologic properties of WY-16, 922, a new orally effective antiallergic agent

The Journal of Pharmacology and Experimental Therapeutics
M E RosenthaleM I Gluckman


In a series of tests designed to illustrate immune reactions similar to those obtained in atopic disease, Wy-16,922 effectively inhibited reaginic-mediated immunologic reactions in the skin, lungs and mast cell. It was found to be devoid of immunosuppressant, antimediator, anti-inflammatory, steroid or bronchodilator properties as well as acute toxicity. Although the mechanism of action of Wy-16,922 is unknown, it appears to limit the release (not the effects) of allergic mediators in a manner similar to that described for disodium cromoglycate.

Related Concepts

Anti-Inflammatory Agents
Antigen-Antibody Reactions
Canis familiaris
Antihistamines, Classical
Histamine Release
Immunosuppressive Agents

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.


Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.